Contemporary Management of Polycystic Ovarian Syndrome.
Androgen Antagonists
/ therapeutic use
Aromatase Inhibitors
/ therapeutic use
Biomarkers
/ blood
Clomiphene
/ therapeutic use
Contraceptives, Oral, Combined
/ therapeutic use
Estrogen Antagonists
/ therapeutic use
Female
Follicle Stimulating Hormone
/ blood
Gonadotropins
/ therapeutic use
Humans
Hypoglycemic Agents
/ therapeutic use
Letrozole
/ therapeutic use
Luteinizing Hormone
/ blood
Metformin
/ therapeutic use
Polycystic Ovary Syndrome
/ diagnosis
Progestins
/ therapeutic use
Sex Hormone-Binding Globulin
/ analysis
Testosterone
/ blood
Journal
Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
18
4
2019
medline:
17
3
2020
entrez:
18
4
2019
Statut:
ppublish
Résumé
PCOS remains one of the most intriguing endocrine disorders that physicians encounter even though it was first described over 80 years ago. Although the diagnostic criteria, nomenclature, and ideal therapeutic strategies are areas of active and ongoing debate, there is no doubt that we have made tremendous progress in improving the quality of life and reproductive outcomes of women who suffer from this wide-ranging disorder.
Identifiants
pubmed: 30994482
doi: 10.1097/GRF.0000000000000449
doi:
Substances chimiques
Androgen Antagonists
0
Aromatase Inhibitors
0
Biomarkers
0
Contraceptives, Oral, Combined
0
Estrogen Antagonists
0
Gonadotropins
0
Hypoglycemic Agents
0
Progestins
0
Sex Hormone-Binding Globulin
0
Clomiphene
1HRS458QU2
Testosterone
3XMK78S47O
Letrozole
7LKK855W8I
Luteinizing Hormone
9002-67-9
Follicle Stimulating Hormone
9002-68-0
Metformin
9100L32L2N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM